for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Bridgebio Pharma’S Qed Therapeutics Presents Data On Infigratinib In Cholangiocarcinoma And Urothelial Carcinoma

May 29 (Reuters) - BridgeBio Pharma Inc:

* BRIDGEBIO PHARMA’S QED THERAPEUTICS PRESENTS DATA ON INFIGRATINIB IN CHOLANGIOCARCINOMA AND UROTHELIAL CARCINOMA AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2020 VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up